All In Biotech

Free tool

FAERS Monitor: Lymphir

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761312 or its brand name (Lymphir, Denileukin Diftitox-Cxdl). Reports on generic versions are filed under their own applications.

Reports

10

Serious

8

80% of reports

Hospitalization

5

Death reported

3

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • capillary leak syndrome3
  • hypoxia2
  • sepsis2
  • acute kidney injury1
  • atrial fibrillation1
  • blood albumin decreased1
  • cognitive disorder1
  • communication disorder1
  • condition aggravated1
  • death1
  • disease progression1
  • enterovirus infection1
  • failure to thrive1
  • hepatic enzyme increased1
  • hypophagia1

Reports by year received

View as table
YearReports
20251
20269

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,149 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
capillary leak syndromeSignal33057.21185.06,356
enterovirus infection12439.6379.6608
communication disorder1550.185.7137
failure to thrive1405.463.1100
blood albumin decreased1265.241.365
hypoxia2119.534.6132
hypophagia182.312.820
cognitive disorder145.07.010
sepsis237.710.940
hepatic enzyme increased130.94.87
atrial fibrillation121.63.44
disease progression117.82.84
acute kidney injury113.72.13
condition aggravated16.91.11
death12.40.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.